Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal
Jeffrey Campsen, Michael A. Zimmerman, James F. Trotter, Michael Wachs, Thomas Bak, Tracy Steinberg, Maria Kaplan, Franklin Wright, Igal Kam – 28 August 2008 – Our center has attempted to minimize corticosteroid (CS) use in all of our orthotopic liver transplantation (OLT) recipients. Because patients with autoimmune hepatitis (AIH) typically require CSs after transplantation, we reviewed our experience in this cohort of patients to determine (1) patient outcomes including recurrent disease and (2) long‐term requirements for CS use in AIH patients.